Antitumor B (ATB), also known as Zeng Sheng Ping, is a Chinese herbal mixture composed of six plants. Previously, clinical studies have shown a significant chemopreventive efficacy of ATB against human esophageal and lung cancers. In the present study, A/J mice harboring a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf and treated with benzo[a]pyrene were used to investigate the chemopreventive effects of ATB on chemically induced lung tumorigenesis. Mice with various genotypes treated with ATB displayed a significant reduction in lung tumor multiplicity and tumor load. Treatment with ATB resulted in an approximately 40% decrease in tumor multiplicity and a 70% decrease in tumor load in both wild-type mice and in mice with a loss of the Ink4a/Arf tumor suppressor genes. Interestingly, ATB decreased tumor multiplicity and volume by 50 and 90%, respectively, in mice with a dominant-negative p53 and in mice with both a p53 mutation and deletion of Ink4a/Arf. Kras2 mutation analysis of the lung tumors revealed that tumors harbored mutations in the 12th codon of Kras2. There were no differences in either the incidence or types of mutations between tumors treated with or without ATB. Oligonucleotide array analysis revealed 284 genes that were differentially expressed in mouse lung tumors as compared to the normal lung, and it was found that 114 out of these 284 genes changed their expression toward the normal levels in tumors treated with ATB. Most of the genes modulated by ATB belong to several cellular signaling pathways, including Notch (Notch homolog 2, manic fringe homolog), growth factor (FGF
Introduction
Lung cancer is the leading cause of cancer death in men and women in the United States (Minna et al., 2002) . Despite advances in detection and treatment, lung cancer patients still have a very poor prognosis. Thus, the overall 5-year survival for newly diagnosed cases of non-small-cell lung cancer (NSCLC) is only 10-15%, while the 5-year cancer-free survival rate is less than 5% (Minna et al., 1989; Hansen and Rorth, 1999) . Thus, prevention is an important part of lung cancer control, especially in high-risk populations such as smokers and former smokers.
Chemoprevention is the use of pharmacologic or naturally occurring agents that inhibit the development of cancer either by blocking cancer initiation by DNAdamaging agents or by arresting or reversing the progression of initiated cells. Most putative chemopreventive agents for lung cancer have been identified in animal models of lung tumorigenesis. The A/J mouse lung model has been used extensively to identify putative chemopreventive agents for lung cancer (You and Bergman, 1998) . Agents that have been examined include steroid hormones, polyphenols and nonsteroidal anti-inflammatory agents (NSAIDs), isothiocyanates, and selenium compounds (You and Bergman, 1998) . In clinical trials in smokers, b-carotene, retinol, vitamin E, and vitamin C appear to exhibit little positive effect on lung cancer incidence, while b-carotene increased the occurrence of lung cancer in current smokers (You and Bergman, 1998) . Similarly, these agents have generally failed to inhibit lung tumorigenesis in rodents. Agents that inhibit lung tumorigenesis, primarily adenomas, in rodents, such as glucocorticoids Estensen, 1996, 1997) , green tea (Shi et al., 1994; Zhang et al., 2002) , NSAID (Castonguay et al., 1998) , and isothiocyanates (Morse et al., 1991) , have either not been evaluated or are being evaluated in humans. Unfortunately, to date, no agent has shown efficacy in preventing human lung cancer in smokers.
The Chinese herbal mixture, Antitumor B (ATB), also known as Zeng Sheng Ping, is a botanical agent composed of six Chinese herbs: Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera. ATB is very effective in chemoprevention of the upper aerodigestive tract tumors in humans and has a long history of safety in thousands of subjects over a period of more than 25 years. Preclinical studies have shown that ATB significantly inhibits N-butyl-(4-hydroxybutyl) nitrosamine (BBN)-induced precancerous lesions of the bladder in rats (Fan, 1993) . Clinical studies showed an approximately 50% reduction in the cancerization rate of marked esophageal dysplasia with ATB (Lin et al., 1990) . In this clinical trial, more than 2500 cases of marked esophageal dysplasia were randomly divided into groups for ATB and placebo, respectively (Lin et al., 1990) . After 3 or 5 years of treatment, the progression of esophageal dysplasia to esophageal cancer was inhibited by a remarkable 52.2 and 47.3%, respectively (Lin et al., 1990) .
Recent studies have shown ATB to be a promising chemopreventive agent in smokers with bronchial dysplasia (Steve Lam, Professor, British Columbia Cancer Agency, Vancouver, Canada. sclam@interchan-ge.ubc.ca; personal communication). In a pilot study of ATB in smokers with bronchial dysplasia, 20 current and former smokers with a smoking history of B30 pack-years with one or more sites of bronchial dysplasia identified by fluorescence bronchoscopy-directed bronchial biopsies were treated with ATB for 6 months. Using combined histopathology and nuclear morphometry as the primary end point, site-specific analysis showed a complete regression rate of 64% in the ATB group and 26% in the placebo group (P ¼ 0.002). The corresponding progressive disease rates were 9 and 12%, respectively. In fact, the response observed with ATB in humans was better than any other compounds (retinol, anethole dithiolethione, and budesonide) that have been evaluated by Dr Lam's group (Steve Lam, personal communication) .
A/J mice harboring a dominant-negative p53 mutation and/or a heterozygous deletion of Ink4a/Arf appear to be an excellent model for human adenocarcinoma of the lung by carrying common genetic alterations found in human lung adenocarcinomas. We found that mice with alterations in both p53 and Ink4a/Arf displayed a striking increase in lung tumor multiplicity and were much more likely to progress to adenocarcinomas compared with mice having only one of the anomalies Zhang et al., 2003) . Using mice with either a germline mutant p53 transgene (p53 val135/wt ), a heterozygous Ink4a/Arf deficiency, or both, on an A/J background, we tested the chemopreventive effects of budesonide and a farnesyl transferase inhibitor (L-778,123) in lung tumorigenesis Zhang et al., 2003) . The objectives of the present investigation were to determine whether ATB has efficacy in preventing chemically induced lung tumorigenesis in mice and whether genetic alterations in p53 and Ink4a/Arf influences lung tumor responsiveness to ATB. As p53 and p16 are among the most common alterations observed in human lung cancer, defects in the tumor suppressor gene p53-and p16-dependent pathways may be a significant impediment to successful cancer prevention, we have employed mouse models that incorporate these molecular lesions. We also determined the expression profiles of mouse lung tumors treated with ATB and have found potential leads that may help elucidate the mechanism of action of this agent.
Results

Dose selection studies of ATB in A/J mice
We performed an 8-week dose selection study and found that ATB was well tolerated in A/J mice. Initial studies (C Grubbs, Univ. Alabama) at doses of 1.56-100 g/kg diet exhibited minimal toxic effects (Figure 1 ). We followed this up by giving diets composed of AIN-76A with ATB at 800, 400, 200, or 100 g/kg diet. Mice given 800 g/kg of ATB were terminated within the first 2 weeks due to body weight loss (420%). These tests were continued for a total of 8 weeks and no significant differences in body weights or clinical evidence of toxicity was observed at doses of 100-400 g/kg diet ( Figure 1 ).
Chemopreventive efficacy of ATB on B[a]P-induced lung tumorigenesis in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf p53 transgenic N10(A/J Â UL53-3) (Ala 135 Val) mice were cross bred with heterozygous Ink4a/Arf deficient N6(A/J Â Ink4a/ArfKO) mice, and F 1 mice with four genotypes, p53
, and p53
, were generated. Mice were initiated with a single dose of B[a]P (100 mg/kg body weight) or vehicle control (tricapryline). Based on the MTD study, all the testing mice were given a nontoxic dose of ATB 300 g/kg in AIN-76A purified diet beginning 2 weeks prior to B[a]P initiation and continuing for the duration of the experiment. Mice were killed 30 weeks after exposure to carcinogens. Consistent with our previous studies Zhang et al., 2003) , B[a]P produced an average of 12-13 tumors per mouse in wild-type (p53 þ / þ Ink4a/ Arf þ / þ ) mice and in mice with a p16 defect (p53
), while yielding 21-23 tumors per mouse in mice with either a p53 dominant-negative mutation (p53
or with both the p53 mutation and heterozygous Ink4a/Arf deficiency (p53 (Figure 2a, b) . There was no difference in tumor Antitumor B is a potent lung cancer chemopreventive agent Z Zhang et al multiplicity between wild-type and heterozygous Ink4a/ Arf deficient mice. There was a significant increase in tumor size in heterozygous Ink4a/Arf deficient mice compared with wild-type mice after 30 weeks exposure to B(a)P (Po0.01). Mice with a dominant-negative p53 mutation demonstrated a striking increase in tumor volume. Interestingly, a synergistic increase in tumor volume was seen in compound mice causing an B30-fold increase in total tumor volume as compared to wildtype mice. This increase in size was significantly associated with an increase in tumor progression. More notably, the majority of the large lung tumors (B80%) from the p53
þ /À mice were adenocarcinomas. In contrast, less than 10% of the lung tumors in the wild-type mice were adenocarcinomas.
The incidences of lung tumors in both the ATB test groups and the B[a]P control groups were 100%. As shown in Figure 2c and d, treatment with ATB produced an average 40-50% inhibition in lung tumor multiplicity, regardless of p53 or Ink4a/Arf genotypes when compared with B[a]P control groups (Po0.01). There were even more striking effects on the total tumor volume, with more than 60% reduction in the wild-type and heterozygous Ink4a/Arf-deficient mice. Interestingly, a greater than 90% decrease in tumor volume was observed in mice with a dominant-negative p53 or in compound mice with both a p53 mutation and a deletion of the Ink4a/Arf. The significance of percent changes was calculated using a Z-statistic for proportions and the data showed that reduction in tumor load in p53
Ink4a/Arf þ /À mice is significantly different from the tumor reductions in p53 wildtype mice (Po0.001). These data reveal that ATB exerts a strong preventive effect when administered during both the preinitiation period and the postinitiation period. These results also indicate that ATB is more effective in inhibiting tumor progression in mice with a dominant-negative p53 mutation.
Pulmonary lesion size correlates with tumor progression
We found that roughly 50% of the lung tumors from either p53
Ink4a/Arf þ / þ mice were adenocarcinomas and pulmonary lesion size closely correlates with tumor progression. This correlation between the size of the lesion and degree of tumor progression is shown in Figure 3 . A total of 10 pulmonary lesions from each: hyperplasias, adenomas, and adenocarcinomas were analysed and tumor sizes were recorded. The histopathological characteristics of these lung lesions are described here. The low-power hyperplasia shows that the septal architecture is maintained to some extent, the lesion is focal and not well demarcated. Under high power, cells show little atypia, and the shape is often cuboidal. Under low power, adenoma features include a papillary pattern with some compression of adjacent parenchyma. Under high power, monomorphic, generally well-differentiated cells supported by fibrovascular stroma are seen. Lung adenocarcinoma has a highly infiltrative character with low power and exhibits a marked cellular atypia and pleomorphism when examined under high magnifications. Figure 3g shows a strong association of tumor diameter with histological typing of either adenomas or adenocarcinomas. Logistic analysis using a generalized Figure 1 Graphs of the body weights of A/J mice receiving ATB during an 8-week dose selection study. ((a) and (b)) This experiment was performed in Dr Grubbs' lab. The control group was fed Teklad diet, while test groups were given a diet composed of ATB at 100, 50, 25, 12.5, 6.25, 3.13, and 1.56 g/kg diet. (c) This experiment was performed in Dr You's lab. The control group was fed AIN-76A purified diet, while test groups were given pure ATB and ATB at 800, 400, 200, and 100 g/kg diet. * Indicates mice with 420% body weight loss that were euthanized by CO 2 asphyxiation (ATB and 800 g/kg group) Antitumor B is a potent lung cancer chemopreventive agent Z Zhang et al linear model shows significant association (Po0.01) with an odds ratio of 1.670.5 per 0.1 mm diameter. The carcinoma frequency was significantly increased among tumors larger than 2.0 mm in diameter. These results show that mice with alterations in p53 or p16 alone promote tumor progression and that compound mice with both a dominant-negative p53 and an Ink4a/Arf deficiency act synergistically. This is the first transgenic mouse model involving three of the most common genetic alterations (Kras2, p53, and Ink4a/Arf) found in human lung NSCLC.
Kras2 mutations in lung tumors from mice with and without ATB Mutation analysis of Kras2 was performed on a total of 11 lung tumors from wild-type mice that were treated with B[a]P and 13 tumors in mice treated with B[a]P þ ATB. A direct sequence analysis showed that most of the tumors harbored mutations in the 12th codon of Kras2, and there was no significant difference in the incidence and types of mutations between tumors in mice treated with and without ATB (Table 1) .
Oligonucleotide array analysis of lung tumors and normal tissues from mice treated with and without ATB Microarray analysis using Affymetrix GeneChips revealed 284 genes differentially expressed during mouse lung tumorigenesis induced by B[a]P. Only lesions from treated and untreated wild-type mice were used to determine the effect of ATB treatment on gene expression profile in mouse lung tumors. Among them, 138 genes were underexpressed, while 146 genes were overexpressed in the mouse lung tumors when using two-fold change and Po0.05 (t-test) as cutoff (Figure 4a) . On comparing the expression of these genes in tumors after ATB treatment, it was found that 114 out of 284 genes changed their expression toward the levels of normal lungs in at least two out of four tumors investigated (Po0.05); the remaining 170 genes did not exhibit any change in tumors treated with ATB ( Figure 4b ). Several cellular pathway-related genes, such as Notch pathway (Notch homolog 2, manic fringe homolog), growth factor (FGF intracellular binding protein, PDGFa), Ras-MAPK pathway (MAPK3, MAP3K4, rab3A, Rap1), G protein pathway (RSG5, PKCy), ubiquitinproteasome pathway (CDC34, Cullin1, 26S protea- Antitumor B is a potent lung cancer chemopreventive agent Z Zhang et al some), apoptosis (BAD promoter, caspase 3), and other genes are modulated to normal levels by ATB (Table 2) . GenMapp search revealed that the G13 pathway is actively involved in ATB's inhibitory role during mouse lung tumorigenesis ( Figure 5 ).
Discussion
As mentioned in the Introduction, there are no agents that have proven useful in preventing lung cancer to date. ATB is an interesting candidate, since it has been shown to inhibit effectively progression of precancerous lesions of human esophagus (dysplasia) to squamous cell carcinoma (SCC) (Lin et al., 1990) . In addition, preliminary unpublished data suggest a similar preventive effect of ATB on human lung precancerous lesions of current and former smokers (Steve Lam, personal communication). The major finding of this study is the observation that ATB is effective in chemoprevention of lung tumorigenesis in mice with defects in p53 and Ink4a/Arf. Secondly, the gene expression profiles of mouse lung tumors treated with and without ATB were determined to provide clues underlying its mechanism of action.
In the present study, we employed wild-type A/J mice or A/J mice with either a dominant-negative mutation in p53 and/or a deficiency in a major cell cycle inhibitor (Ink4a/Arf). We determined that long-term administration of ATB in the diet has chemopreventive effects on Antitumor B is a potent lung cancer chemopreventive agent Z Zhang et al chemically induced lung tumorigenesis, and further examined whether p53 and Ink4a/Arf influence lung tumor responsiveness to ATB. ATB significantly reduced tumor multiplicity by 40-50%, regardless of p53 and Ink4a/Arf genotypes. These data show that the efficacy of ATB is independent of genetic alterations in p53 or Ink4a/Arf since we observed striking preventive activity in lesions with either or both genetic lesions. We also found that ATB was well tolerated in A/J mice with doses as high as 400 g/kg diet. Our results are consistent with the long history (426 years) of its safety profile in clinical trials and in its use as herbal supplements. The major inhibitory effect of lung tumorigenesis is clearly caused by treatment with ATB, and it is possible that some of the effects might also be attributable to the fact that the proportion of fat and protein in ATB diet is lower than the control diet. Although it is not statistically significant, the body weight of the mice treated with ATB appears to be lower than that of mice treated with AIN-76A control diet ( Figure 1 ). ATB had even more striking effects on the progression stage of tumor development. Thus, administration of ATB resulted in a significant reduction in tumor volume, by approximately 60% in the wild-type and heterozygous Ink4a/Arf-deficient mice, and more than 90% reduction in p53 transgenic mice and mice carrying both a dominant-negative p53 mutation and heterozygous deletion of the Ink4a/Aaf locus. Concomitant with this striking reduction in tumor volume, a striking decrease in the percentage of tumors that were adenocarcinomas were observed (Data not shown). Clearly, ATB can modulate lung tumorigenesis in mice with greatly increased genetic susceptibility to cancer; that is, in this case due to the inactivation of the wildtype p53 tumor suppressor by the dominant-negative p53 val135/wt mutant, and/or loss of Ink4a/Arf tumor suppressors. This is important since mutation in p53 is commonly associated with resistance to many cancer therapies. We have recently shown that the glucocorticoid budesonide was substantially less effective in the treatment of tumors with a p53 mutation as contrasted with wild-type tumors employing these same models . Since p53, Kras2, and p16 appear to be the most commonly mutated genes in human NSCLC, agents that are effective in tumors with these mutations are particularly appealing.
Our results are consistent with two clinical studies using ATB (Lin et al., 1990, Steve Lam, personal communication) . In both esophageal and lung cancer chemoprevention trials, ATB showed strong chemopreventive efficacy against both tumor types, causing inhibition of precancerous lesions of the esophagus (dysplasia) to SCC, and regression of dysplastic lesions (Lin et al., 1990) . ATB exhibits a significant reduction in the progression rate of the precancerous lesions in lung cancer trials (Steve Lam, personal communication) . In addition, ATB strongly inhibited BBN-induced precancerous lesions in the bladder of rats (Fan, 1993) . Taken together, these results suggest that ATB may be a strong candidate chemopreventive agent, especially for lung cancer.
The present in vivo data clearly demonstrate that ATB is an effective preventive agent in the lung and are consistent with a hypothesis that this agent decreases cell proliferation, increases cell apoptosis, or both. The specific mechanism(s) for the observed chemopreventive effects of ATB is unknown. We performed some initial in vitro studies with ATB, which showed that ATB inhibits cell growth and causes cell cycle arrest in the G2M phase (unpublished data). ATB component analysis recently showed that the major known chemicals are phytosterols (PS), flavones, alkaloids, sapogenins, triterpenes, and triterpenoids (Steve Lam, personal communication) . Furthermore, these analyses by Dr Lam showed that multiple samples of ATB yielded a highly consistent HPLC pattern. Most of these classes of agents are known to have antimutagenic, anti-inflammatory, and procell differentiation effects. For example, epidemiologic and experimental studies suggest that dietary PS may offer protection from the most common cancers (Awad and Fink, 2000) . Furthermore, both in vitro and in vivo studies suggest that b-sitosterol and campesterol, which are PSs, offer protection from colon (Raicht et al., 1980) , prostate (Awad et al., 2000a) , and breast cancers (Awad et al., 2000b) . Functional analysis revealed that these compounds can stimulate apoptosis in breast and prostate cancer cells (Rao and Janezic 1992; von Holtz et al., 1998) , reduce metastasis in MDA-MB-231 cells implanted in SCID mice (Awad et al., 2000c) , and inhibit cell growth. One mechanism for their actions is the induction of cell cycle arrest at the G2/M phase in breast tumor MDA-MB-231 cells (Awad et al., 2001) . PS is regarded as one of the active compounds in ATB and studies have reported clues on the mechanism(s) by which PS produce these anticancer effects (Awad and Fink, 2000) . These include the effect of PS on membrane structure, fluidity and integrity; on signal transduction pathways that regulate tumor (Awad and Fink, 2000) . To identify specific genes or pathways that may contribute to ATB's protective effect, altered gene expression in lung tumors treated with ATB was investigated. Microarray together with the GenMAPP analysis revealed that ATB may affect several cellular processes involved in the tumorigenesis, possibly through the interplay among the ubiquitin-proteasome pathway, Notch pathway, G13 pathway, and Ras-MAPK pathway. Specifically, CDC34, Cullin1, Notch homolog 2, Manic fringe homolog, FGF intracellular binding protein, RGS5, PKC-y, Rap1, MAP3K4, and MAPK3 are found to be modulated towards levels observed in normal lung in tumors treated with ATB. For example, G13 proteins regulate multiple cell-type dependent intracellular and cellular events, including mitogenesis and neoplastic transformation (VoynoYasenetskaya et al., 1994) , apoptosis (Berestetskaya et al., 1998) , and regulation of the ERK and JNK pathways (Voyno-Yasenetskaya et al., 1996) . GenMapp showed 10 genes involved in G13 pathway, which were effectively modulated back to the levels of normal lungs by ATB treatment (eight overexpressed genes and two underexpressed genes) ( Figure 5 ). Crosstalk of these cellular processes may be involved in the lung tumorigenesis. Although the exact mechanism of ATB is still not clear, our data show that ATB can affect cell proliferation, differentiation, and apoptosis by modulation of the interplay among several cellular signaling pathways, especially the G13, Notch, and MAPK.
Further studies will examine these gene effects in tumors of different genetic backgrounds.
In conclusion, this study demonstrated that ATB is a potent lung cancer chemopreventive agent in p53-, Ink4a/Arf-containing and p53-, Ink4a/Arf-deficient mice. ATB's inhibitory effects appear to occur mainly in the tumor progression stage through a p53-, Ink4a/ Arf-independent pathway. Our findings should encourage continued efforts to discover the chemopreventive effects of ATB on other types of cancers.
Materials and methods
Reagents
Benzo[a]pyrene (B[a]P) was purchased from Aldrich Chemical Co. (Milwaukee, WI, USA). Tricaprylin was purchased from Sigma Chemical Co. (St Louis, MO, USA). The putative chemopreventive agent, ATB, was purchased from the Cancer Institute, the Chinese Academy of Medical Sciences (Beijing, P R China). The consistency and quality control studies of ATB were determined previously by Dr Lam's group (Stephen Lam, personal communication) . This study was performed by obtaining HPLC fingerprints for several ATB batches from the manufacturer over the course of a year and demonstrated consistency of the formulation.
Animal models
A/J mice were obtained from the Jackson Laboratories (Bar Harbor, ME, USA). The N10(A/J Â UL53-3) mice were produced by backcrossing UL53-3 mice (p53 transgenic mice) to A/J strain for a total of 10 times. UL53-3 mice carrying a Figure 5 GenMAPP G13 pathways integrating our expression data (cutoff: fold change 42). Yellow indicates that overexpressed genes in B[a]P-induced tumors were modulated to normal levels after ATB treatment. Blue indicates that underexpressed genes in B[a]P-induced tumors were modulated to normal levels after ATB treatment. Gray indicates that the selection criteria were not met, but the gene is represented on the array. White boxes indicate that the gene was not present on the chip 135val p53 mutation were obtained from the National Institute of Environmental Health Sciences, National Institutes of Health (Research Triangle Park, NC, USA). The animals were paired to set up breeding colonies for the production of (A/J Â UL53-3) F 1 mice and further crossbred with A/J mice. After 10 generations of backcrossing to A/J mice, heterozygote N10(A/J Â UL53-3) p53
þ /À mice were used as breeders to generate the N10(A/J Â UL53-3) Â N6(A/J Â Ink4a/ArfKO) F 1 mice.
Ink4a/Arf deficient mice were obtained from Dana Farber Cancer Institute, Boston, MA, USA and were rederived onto the A/J background through six generations of backcrossing. The A/J mouse is highly susceptible to lung tumor induction by certain chemical carcinogens. Since the tumor spectrum found in several knockout mice was similar, including fibrosarcomas, lymphomas, and sarcomas, the mouse background may partially contribute to the observed tumor spectrum. By using A/J mice, we expect that most resulting tumors developed in these mice would be lung tumors as seen in p53 transgenic mice. After six generations of backcrossing to A/J mice, heterozygote N6(A/J Â Ink4a/Arf KO) mice were used as breeders to generate the N10(A/J Â UL53-3) Â N6(A/J Â Ink4a/Arf KO) F 1 mice. Theoretically, the N10(A/J Â UL53-3) mouse is 99.9% A/J background and the N6(A/J Â Ink4a/Arf KO) mouse is 98.44% A/J background (Markel et al., 1997) .
Genotyping
Tail clippings from each N10(A/J Â UL53-3) Â N6(A/J Â Ink4a/Arf KO) F 1 mouse were homogenized and incubated overnight at 371C in lysis solution (pronase 0.4 mg/ml, 10% sodium dodecylsulfate (w/v), 10 mM Tris, 400 mM NaCl, and 2 mM EDTA) followed by phenol-chloroform extraction and precipitation with ice-cold alcohol. To distinguish the p53 transgenic mice from nontransgenic littermates, DNA was extracted from F 1 mouse tails by the proteinase K-sodium dodecylsulfate method, and was genotyped using the PCR-RFLP as described previously (Zhang et al., 2000) . Ink4a/Arf genotypes of the mice were tested by the polymerase chain reaction (PCR) as described previously (Zhang et al., 2002) .
Preliminary toxicology of ATB in A/J mice
Our two laboratories performed 8-week preliminary toxicology studies of ATB independently to determine the maximum tolerated doses (MTD). A/J mice (6 weeks old) were obtained from Harlan Sprague-Dawley, Inc. (Dr Grubbs) and Jackson Laboratories (Dr You). The control group was fed Teklad (Dr Grubbs) or AIN-76A purified diets (Dr You). Test groups were given pure ATB and diets containing ATB at 800, 400, 200, 100, 50, 25, 12.5, 6.25, 3.13 , or 1.56 g/kg diet. Dr Grubbs' group performed dose selection studies from 100 to 1.56 g/kg diet; Dr You's group performed dose selection studies from pure ATB to 100 g/kg. Five animals were used in each testing group. The test diets were continued for 8 weeks. However, mice that demonstrated a 20% body weight loss were euthanized by CO 2 asphyxiation. Animals were housed in plastic cages with hardwood bedding and dust covers, in a HEPA filtered, environmentally controlled room (24711C, 12/ 12 h light/dark cycle). Body weights were monitored weekly for the duration of the studies. All food and water were available ad libitum.
Chemoprevention studies
Animals used in this study were F1 mice generated by crossing N10(A/J Â UL53-3) and N6(A/J Â Ink4a/ArfKO) mice. All the animals were genotyped for p53 and Ink4a/Arf by PCR or PCR-RFLP as previously described (Zhang et al., 2000 (Zhang et al., , 2002 . N10(A/J Â UL53-3) Â N6(A/J Â Ink4a/ArfKO) F1 mice (6 weeks old) were randomized into a tricaprylin (vehicle) control group and B[a]P treatment groups based upon the genotype and gender. The tricaprylin control group was fed AIN-76A Purified Diet #100 000 (Dyets Inc, Bethlehem, PA, USA). All carcinogen-treated mice were given a single i.p. dose of B[a]P (100 mg/kg body weight) in 0.1 ml tricaprylin. One half of the B[a]P-treated mice were fed AIN-76A Purified Diet #100 000 only. Testing mice were given ATB 300 g/kg in AIN-76A purified diet 2 weeks before B[a]P treatment and for the duration of the experiment. For preparation of diets, experimental diet was prepared once per week. The control diet, AIN-76A purified diet, consisted of 20% casein, 0.3% D,Lmethionine, 52% cornstarch, 13% dextrose, 5% corn oil, 5% alphacel, 3.5% AIN mineral mixture, 1% AIN vitamin mixture, and 0.2% choline bitartrate. For the ATB diet, powdered AIN-76A purified diet was mixed together with ATB powder for 30-45 min in an Ultra-Power food mixer (model: KSM90BU) set at medium speed. Food was changed every other day and food jars were changed once per week. Mice were killed 30 weeks after exposure to carcinogens by CO 2 asphyxiation. Portions of tumor and normal tissue were frozen at À801C. The remaining lung was fixed in Tellyesniczky's (90% ethanol (70% v/v), 5% glacial acetic acid, 5% formalin (10% v/v buffered formalin) solution overnight, followed by 70% EtOH. Lung tumor development was estimated by measuring number (N), volume (V), and total tumor load (N Â V).
Analysis of Kras2 mutations by PCR-direct sequencing
DNA was isolated from lung tumors using the TRIzol (Gibco BRL). Sequences of PCR primers for Kras2 exons 1 were described previously (18). Briefly, a 100 ml reaction mixture containing 100 ng genomic DNA, 10 mM Tris-HCl, pH 8.5, 50 mM KCl, 2.5 mM MgCl 2 , 100 mM of each deoxyribonucleoside triphosphate (dATP, dCTP, dGTP, dTTP), 1.0 U of Taq DNA polymerase (Promega, Madison, WI, USA), and 40 pmol of each primer was overlaid with sterile mineral oil and subjected to 35 cycles of PCR amplification. Each cycle consisted of 1 min each at 94, 55, and 721C. The 12th codon mutations were analysed with an ABI PRISM 3700 DNA analyser (PE Applied Biosystems, Foster City, CA, USA).
RNA isolation and amplification
Total RNA from each sample was isolated by Trizol (Invitrogen, Carlsbad, CA, USA) and purified using the RNeasy Mini Kit and RNase-free DNase Set (QIAGEN, Valencia, CA, USA) according to the manufacturer's protocols. In vitro transcription-based RNA amplification was then performed on each sample. cDNA for each sample was synthesized using a Superscript cDNA Synthesis Kit (Invitrogen) and a T7-(dT)24 primer: 5 0 -GGCCAGT-GAATTGTAATACGACT-CACTATAGGGAGGCGG-(dT) 24-3 0 . The cDNA was cleaned using phase-lock gel (Fisher Cat ID E0032005101) phenol/chloroform extraction. Then, the biotin-labeled cRNA was transcribed in vitro from cDNA using a BioArray HighYield RNA Transcript Labeling Kit (ENZO Biochem, New York, NY, USA) and purified, again using the RNeasy Mini Kit.
Affymetrix GeneChip s probe array
The labeled cRNA was applied to the Affymetrix Mu74Av2 GeneChips (Affymetrix, Santa Clara, CA, USA), which contains 412 000 genes and ESTs on one array according to the manufacturer's recommendations. Every gene or EST is represented by a probe set consisting of approximately 16 probe pairs (oligonucleotides) of 25-mer oligonucleotides. One sequence of a probe pair represents the complementary strand of the target sequence, while the other has a one base pair mismatch at the central base pair position. This mismatch sequence serves as an internal control for specificity of hybridization.
Cluster and GenMapp
Four independent samples were collected for each group. Array normalization and gene expression estimates were obtained using Affymetrix Microarray Suite 5.0 software (MAS5). The array mean intensities were scaled to 1500. These estimates formed the basis for statistical testing. Differential expression was determined on the combined basis of statistical testing using t-test and on the basis of a ratio with a cutoff of Po0.05 and fold X2 being called positive for differential expression. For the selected genes, expression indexes were transformed across samples to an N (0,1) distribution using a standard statistical Z-transform. These values were input to the GeneCluster program of Eisen et al. (1998) and genes were clustered using average linkage and correlation dissimilarity. Signal transduction pathways, metabolic pathways, and other functional groupings of genes were evaluated for differential regulation using the visualization tool GenMAPP (UCSF, www.genmapp.org). GenMAPP is a recently reported tool for visualizing expression data in the context of biological pathways (Dahlquist et al., 2002) . We imported the statistical results of our data set into the program and used GenMAPP to illustrate pathways containing differentially expressed genes. Differential gene expression was based on ATB treatment versus nontreatment expression change (fold change 42).
Statistical analysis
Student's t-test was used to determine differences in the number and size of lung tumors per mouse between the treated and control mice. The significance of percent changes was calculated using a Z-statistic for proportions Z ¼p p 1 Àp p 2 ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffif p pð1 Àp pÞð1=n 1 þ 1=n 2 Þ p where pˆ1 is the proportional reduction due to ATB in the wildtype group, pˆ2 is the proportional reduction due to ATB in the transgenic groups, pˆis the proportional reduction due to ATB regardless of genotype, and n 1 is the number of wild-type animals and n 2 the number of transgenic animals.
